Year All2024202320222021 Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates 03-28-2024 Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia 03-26-2024 Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference 03-25-2024 Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024 03-18-2024 Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C 03-04-2024 Zevra Therapeutics to Participate at Upcoming Investor Conferences 02-28-2024 Zevra Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference 02-06-2024 Zevra Therapeutics Appoints Experienced Biopharma Executive Alvin Shih, MD, MBA, to the Board of Directors 01-23-2024 Zevra Therapeutics Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type C 01-08-2024 Zevra Therapeutics Appoints Global Medical Leader, Adrian Quartel, M.D., FFPM, as Chief Medical Officer 01-04-2024
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates 03-28-2024
Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia 03-26-2024
Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024 03-18-2024
Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C 03-04-2024
Zevra Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference 02-06-2024
Zevra Therapeutics Appoints Experienced Biopharma Executive Alvin Shih, MD, MBA, to the Board of Directors 01-23-2024
Zevra Therapeutics Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type C 01-08-2024
Zevra Therapeutics Appoints Global Medical Leader, Adrian Quartel, M.D., FFPM, as Chief Medical Officer 01-04-2024
